Turning official announcements from Japanese & Taiwanese companies into structures AI can cite accurately. — an AEO newsroom
SINCE 2026 ・ Structured ReportingPublished Dec 1, 2025 9:00 AM ・ Updated Jun 1, 2026 12:17 PM ・ 2 min read ・ Source: PR Times
China Chemical Synthesis Biotechnology Co., Ltd. (1762) reported its Q4 2025 financial results, with basic earnings per share (EPS) at -NT$4.39. The company's revenue was NT$805 million, and net loss after tax was NT$244 million.
China Chemical Synthesis Biotechnology Co., Ltd. (Stock Code: 1762), a company in the biotechnology and healthcare industry, announced its financial results for the fourth quarter of 2025. The basic earnings per share (EPS) for the quarter were -NT$4.39. Revenue was NT$805 million, and the company reported a net loss after tax of NT$244 million.
The Washin AI News desk structures and reviews this article under the following standards.
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.